SG11201909811XA - Heterocyclic compound - Google Patents

Heterocyclic compound

Info

Publication number
SG11201909811XA
SG11201909811XA SG11201909811XA SG11201909811XA SG 11201909811X A SG11201909811X A SG 11201909811XA SG 11201909811X A SG11201909811X A SG 11201909811XA SG 11201909811X A SG11201909811X A SG 11201909811XA
Authority
SG
Singapore
Prior art keywords
heterocyclic compound
calcium
expected
salt
useful
Prior art date
Application number
Inventor
Shuji Kitamura
Zenichi Ikeda
Minoru Ikoma
Koji Watanabe
Hideki Hirose
Takafumi Yukawa
Sachie Morimoto
Naoki Nishizawa
Taiji Asami
Original Assignee
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceuticals Co filed Critical Takeda Pharmaceuticals Co
Publication of SG11201909811XA publication Critical patent/SG11201909811XA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Abstract

Heterocyclic compound The present invention provides a compound or a salt thereof having a calcium-sensing receptor antagonistic activity, and being expected to be useful as an agent for preventing or treating heart failure, pulmonary hypertension, or the like. The compounds represented by formula (I) or a salt thereof has a calcium-sensing receptor antagonistic activity, and is expected to be useful as an agent for preventing or treating heart failure, pulmonary hypertension, or the like, wherein each symbol is as described in the specification. [No suitable figure]
SG11201909811X 2017-04-27 2018-04-26 Heterocyclic compound SG11201909811XA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2017087950 2017-04-27
PCT/JP2018/016996 WO2018199236A1 (en) 2017-04-27 2018-04-26 Heterocyclic compound

Publications (1)

Publication Number Publication Date
SG11201909811XA true SG11201909811XA (en) 2019-11-28

Family

ID=63918548

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201909811X SG11201909811XA (en) 2017-04-27 2018-04-26 Heterocyclic compound

Country Status (14)

Country Link
US (1) US20210115048A1 (en)
EP (1) EP3617208A4 (en)
JP (1) JP7177043B2 (en)
CN (1) CN110582499B (en)
AU (1) AU2018257332B2 (en)
BR (1) BR112019022457A2 (en)
CA (1) CA3061590A1 (en)
CO (1) CO2019012295A2 (en)
IL (1) IL270154B (en)
MX (1) MX2019012810A (en)
SA (1) SA519410385B1 (en)
SG (1) SG11201909811XA (en)
WO (1) WO2018199236A1 (en)
ZA (1) ZA201907793B (en)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA902280B (en) * 1989-03-29 1990-12-28 Merrell Dow Pharma Selective adenosine receptor agents
KR101050700B1 (en) * 2002-08-26 2011-07-20 다케다 야쿠힌 고교 가부시키가이샤 Calcium receptor modulating compounds and uses thereof
ZA200500782B (en) * 2002-08-26 2007-10-31 Takeda Pharmaceutical Calcium receptor modulating compound and use thereof
JP2005239611A (en) * 2004-02-25 2005-09-08 Takeda Chem Ind Ltd Pyrazolopyrimidine derivative and its application
WO2009073210A1 (en) * 2007-12-06 2009-06-11 Intra-Cellular Therapies, Inc Organic compounds
WO2009155448A1 (en) * 2008-06-20 2009-12-23 Ligand Pharmaceuticals Inc. Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists
WO2014061676A1 (en) * 2012-10-16 2014-04-24 武田薬品工業株式会社 Heterocyclic compound
CN104910118B (en) * 2014-03-13 2017-07-04 中国科学院上海药物研究所 One marcumar class compound and its production and use

Also Published As

Publication number Publication date
EP3617208A1 (en) 2020-03-04
US20210115048A1 (en) 2021-04-22
MX2019012810A (en) 2022-06-03
AU2018257332A1 (en) 2019-11-14
SA519410385B1 (en) 2023-02-07
CN110582499A (en) 2019-12-17
ZA201907793B (en) 2022-03-30
RU2019138176A3 (en) 2021-07-16
EP3617208A4 (en) 2020-08-26
CO2019012295A2 (en) 2020-02-28
BR112019022457A2 (en) 2020-05-12
JP7177043B2 (en) 2022-11-22
RU2019138176A (en) 2021-05-27
AU2018257332B2 (en) 2021-11-04
IL270154B (en) 2022-07-01
WO2018199236A1 (en) 2018-11-01
CA3061590A1 (en) 2018-11-01
CN110582499B (en) 2022-04-29
IL270154A (en) 2019-12-31
JPWO2018199236A1 (en) 2020-03-12

Similar Documents

Publication Publication Date Title
PH12020500236A1 (en) Heterocyclic compund and use thereof
PH12018501666A1 (en) Substituted piperidine compound and use thereof
PH12017502407B1 (en) Fused pyrimidine compound or salt thereof
MY192603A (en) 1,3-benzodioxole derivative
MX2015014204A (en) Substituted pyrimidinium compounds and derivatives for combating animal pests.
PH12015501585A1 (en) Manufacturing process for pyrimidine derivatives
WO2015142001A3 (en) Compound having cardiotonic activity and pharmaceutical composition for preventing or treating heart failure, containing same
MX2018007418A (en) Benzamide compounds and their use as herbicides.
MX2021008241A (en) Heterocyclic compound and use thereof.
MX2016009794A (en) Heterocyclic sulfonamide derivative and medicine comprising same.
PH12019502248A1 (en) Ip6k inhibitors
MY162886A (en) Novel tetrahydropyridopyrimidine compound or salt thereof
JO3442B1 (en) Antagonists of somatostatin receptor subtype 5 (sstr5)
MX2018001517A (en) Substituted guanidine derivative.
MX2018001317A (en) Respiratory syncytial virus inhibitors.
PH12015501146A1 (en) Hydantoin derivative
MX2015017637A (en) Substituted pyrimidinium compounds and derivatives for combating animal pests.
MX2018007415A (en) Methods for preparing substituted 5,6-dihydro-6-phenylbenzo[f]iso quinolin-2-amine.
WO2016023028A3 (en) G protein-coupled receptor kinase 2 inhibitors and methods for use of the same
SG11201909812VA (en) Heterocyclic compound
PH12015501643B1 (en) Methods of use of phenoxypropylamine compounds to treat depression
SG11201909811XA (en) Heterocyclic compound
MX369104B (en) New Compounds.
MX2019007786A (en) Substituted guanidine compound.
MX2016016765A (en) Rodentia animal repellent.